Economic evaluation of type 2 diabetes mellitus burden and its main cardiovascular complications in the Russian Federation
Open Access
- 2 December 2016
- journal article
- Published by Endocrinology Research Centre in Diabetes mellitus
- Vol. 19 (6) , 518-527
Abstract
Background. Diabetes Mellitus Type 2 (DMT2) is a complex medical and social problem in the world and in the Russian Federation also due to prevalence and probability of cardio-vascular complications (CVC).Aim. Economic burden evaluation of DMT2 in the Russian Federation.Methods. Complex analysis of expenditures (direct and non-direct costs) based on epidemiological, pharmacoeconomics and clinical investigations, population and medical statistics data.Results. Calculated expenditures for DMT2 are 569 bln RUR per year, that is correspond to 1% of the Russian GDP, and 34,7% of that are expenditures for main CVC (ischemic heart disease, cardiac infarction, stroke). Main part of expenses are non-medical (losses GDP) due to temporary and permanent disability, untimely mortality – 426,7 bln RUR per year. Expenditures in estimated group of patients with non-diagnosed DMT2 but with already having CVC were at least 107 bln per year (18,8% from total cost). Relationship between cost of DMT2 and degree of it’s control was found in the Russian conditions. Estimated cost for compensated patient (HbA1c6,5%) per year was 88 982 RUR, in the same time cost of non-control patient (HbA1c9,5%) was in 2,8 times higher due to more often main CVC in this group.Conclusion. DMT2 diagnosis improvement as well as effective treatment of early stages of illness can decrease probability of CVC and social economic expenditures.Keywords
This publication has 18 references indexed in Scilit:
- Once-weekly administration of dulaglutide, a glucagon-like peptide-1 receptor agonist, as monotherapy and combination therapy: review of the AWARD studiesDiabetes mellitus, 2017
- Prevalence of type 2 diabetes mellitus (T2DM) in the adult Russian population (NATION study)Diabetes Research and Clinical Practice, 2016
- The prevalence of type 2 diabetes mellitus in the adult population of Russia (NATION study)Diabetes mellitus, 2016
- Hypoglycemia Event Rates: A Comparison Between Real-World Data and Randomized Controlled Trial Populations in Insulin-Treated DiabetesDiabetes Therapy, 2016
- Diabetes mellitus as an economic problem in Russian FederationDiabetes mellitus, 2016
- National register of diabetes mellitus in Russian Federation.Diabetes mellitus, 2015
- The impact of diabetes‐related complications on healthcare costs: new results from the UKPDS (UKPDS 84)Diabetic Medicine, 2015
- Health Economic Evaluation of Type 2 Diabetes Mellitus: A Clinical Practice Focused ReviewClinical Medicine Insights: Endocrinology and Diabetes, 2015
- Achieving HbA1c targets in clinical trials and in the real world: a systematic review and meta-analysisJournal of Endocrinological Investigation, 2014
- Pharmacoeconomic assessment of type 2 diabetes mellitus care on the base of Endocrinology Research Centre, MoscowDiabetes mellitus, 2012